SCHEDULE: Vanguard Group Discloses 5.04% Stake in Capricor Therapeutics
Beneficial Ownership Report
The Vanguard Group has reported a beneficial ownership of 5.04% in Capricor Therapeutics Inc., holding over 2.3 million shares of common stock.
Summary
- The Vanguard Group, an investment adviser based in Pennsylvania, has filed a Schedule 13G disclosing its beneficial ownership in Capricor Therapeutics Inc.
- As of June 30, 2025, Vanguard beneficially owned an aggregate of 2,305,078 shares of Capricor Therapeutics Inc. Common Stock.
- This ownership represents 5.04% of the total outstanding shares of Capricor Therapeutics Inc.
- Vanguard holds sole voting power over 0 shares, shared voting power over 45,498 shares, sole dispositive power over 2,216,456 shares, and shared dispositive power over 88,622 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It is a factual report of an institutional investor's stake.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by a major institutional asset manager, The Vanguard Group, in Capricor Therapeutics Inc., a company operating in the biotechnology sector. Such disclosures are common for large index fund managers and typically reflect portfolio allocation rather than a specific strategic move related to the issuer's industry position.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like Vanguard may be viewed positively, potentially signaling confidence in the company's long-term prospects, especially for existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (reporting period end date for ownership stake). |
| 07/29/2025 | Date the Schedule 13G statement was signed by The Vanguard Group. |
Keywords
Capricor Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.